Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Receivables: 2009-2024

Historic Change in Receivables for Heron Therapeutics (HRTX) over the last 12 years, with Dec 2024 value amounting to $18.7 million.

  • Heron Therapeutics' Change in Receivables rose 116.73% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.0 million, marking a year-over-year increase of 331.81%. This contributed to the annual value of $18.7 million for FY2024, which is 131.75% up from last year.
  • Latest data reveals that Heron Therapeutics reported Change in Receivables of $18.7 million as of FY2024, which was up 131.75% from $8.1 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Change in Receivables registered a high of $18.7 million during FY2024, and its lowest value of -$6.4 million during FY2021.
  • Its 3-year average for Change in Receivables is $14.5 million, with a median of $16.6 million in 2022.
  • In the last 5 years, Heron Therapeutics' Change in Receivables tumbled by 422.22% in 2021 and then surged by 360.59% in 2022.
  • Over the past 5 years, Heron Therapeutics' Change in Receivables (Yearly) stood at $2.0 million in 2020, then crashed by 422.22% to -$6.4 million in 2021, then skyrocketed by 360.59% to $16.6 million in 2022, then tumbled by 51.13% to $8.1 million in 2023, then spiked by 131.75% to $18.7 million in 2024.